Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
2.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, Gastinne T, Le Bris Y, Lok A, Bonnet A, Le Gouill S, Moreau P, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2019 Mar 27. pii: S1083-8791(19)30209-5. doi: 10.1016/j.bbmt.2019.03.025. [Epub ahead of print]

PMID:
30928627
3.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.

Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14.

PMID:
30874851
4.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.

PMID:
30874850
5.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
6.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
7.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

8.

Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.

Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Bonnet A, Béné MC, Gouill SL, Moreau P, Kraeber-Bodéré F, Chevallier P.

Biol Blood Marrow Transplant. 2019 May;25(5):906-911. doi: 10.1016/j.bbmt.2018.11.019. Epub 2018 Nov 24.

PMID:
30481598
9.

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.

Chevallier P, Peterlin P, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Le Bris Y, Béné MC, Le Gouill S, Moreau P, Guillaume T.

Oncotarget. 2018 Sep 11;9(71):33528-33535. doi: 10.18632/oncotarget.26083. eCollection 2018 Sep 11.

10.

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.

Peterlin P, Guillaume T, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Gallas P, Touzeau C, Gastinne T, Lok A, Thomare P, Chauvin C, Le Gouill S, Moreau P, Chevallier P.

Leuk Res Rep. 2018 Jan 17;9:16-17. doi: 10.1016/j.lrr.2018.01.002. eCollection 2018. No abstract available.

11.

CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms.

Debord C, Robillard N, Theisen O, Gastinne T, Godmer P, Graveleau J, Le Gouill S, Luycx O, Tiab M, Loirat M, Lestang E, Wuillème S, Godon C, Eveillard M, Béné MC.

Hematol Oncol. 2018 Apr 15. doi: 10.1002/hon.2511. [Epub ahead of print] No abstract available.

PMID:
29656538
12.

Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial.

Carras S, Dubois B, Senecal D, Jais JP, Peoc'h M, Quittet P, Foussard C, Bouabdallah K, Gastinne T, Jourdan E, Sanhes L, Ertault M, Lamy T, Molina L.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):191-198. doi: 10.1016/j.clml.2018.01.003. Epub 2018 Jan 31.

PMID:
29502594
13.

Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.

Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G.

Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.

14.

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.

Van Den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Ghesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F.

Haematologica. 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554. Epub 2018 Jan 19.

15.

Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.

Peterlin P, Chauvin C, Le Gouill S, Pere M, Dalichampt M, Guillaume T, Garnier A, Paré M, Le Bourgeois A, Moreau P, Chevallier P, Deslandes G, Gastinne T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01746-17. doi: 10.1128/AAC.01746-17. Print 2018 Feb.

16.

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O; LYSA Group.

N Engl J Med. 2017 Sep 28;377(13):1250-1260. doi: 10.1056/NEJMoa1701769.

17.

Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016).

Bourcier J, Heudes PM, Morio F, Gastinne T, Chevallier P, Rialland-Battisti F, Garandeau C, Danner-Boucher I, Le Pape P, Frampas E, Moreau P, Defrance C, Peterlin P.

Mycoses. 2017 Aug;60(8):526-533. doi: 10.1111/myc.12624. Epub 2017 Apr 21.

PMID:
28429890
18.

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.

Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2017 Jun;96(6):943-950. doi: 10.1007/s00277-017-2981-2. Epub 2017 Apr 3.

PMID:
28374163
19.

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Lestang E, Peterlin P, Le Bris Y, Dubruille V, Delaunay J, Godon C, Theisen O, Blin N, Mahe B, Gastinne T, Garnier A, Touzeau C, Voldoire M, Bene MC, Le Gouill S, Milpied N, Mohty M, Moreau P, Guillaume T, Chevallier P.

Eur J Haematol. 2017 Jul;99(1):60-69. doi: 10.1111/ejh.12891. Epub 2017 May 5.

PMID:
28370306
20.

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.

Garnier A, Guillaume T, Peterlin P, Béné MC, Le Bris Y, Dubruille V, Mahé B, Gastinne T, Touzeau C, Blin N, Le Gouill S, Moreau P, Chevallier P.

Bone Marrow Transplant. 2017 Jul;52(7):1063-1064. doi: 10.1038/bmt.2017.60. Epub 2017 Apr 3. No abstract available.

PMID:
28368382
21.

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.

Damaj G, Cornillon J, Bouabdallah K, Gressin R, Vigouroux S, Gastinne T, Ranchon F, Ghésquières H, Salles G, Yakoub-Agha I, Gyan E.

Bone Marrow Transplant. 2017 Jul;52(7):941-949. doi: 10.1038/bmt.2016.340. Epub 2017 Jan 23. Review.

PMID:
28112752
22.

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Touzeau C, Le Gouill S, Mahé B, Boudreault JS, Gastinne T, Blin N, Caillon H, Dousset C, Amiot M, Moreau P.

Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5. No abstract available.

23.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):140-146. doi: 10.1016/j.bbmt.2016.10.011. Epub 2016 Oct 14.

24.

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients.

Peterlin P, Guillaume T, Delaunay J, Mohty M, Garnier A, Mahe B, Dubruille V, Blin N, Voldoire M, Touzeau C, Chauvin C, Gastinne T, Béné MC, Le Gouill S, Moreau P, Chevallier P.

Semin Hematol. 2016 Jul;53(3):216-7. doi: 10.1053/j.seminhematol.2016.06.001. Epub 2016 Jun 18. No abstract available.

PMID:
27496314
25.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Voldoire M, Guillaume T, Peterlin P, Gallas P, Garnier A, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2016 Aug;95(8):1287-93. doi: 10.1007/s00277-016-2705-z. Epub 2016 Jun 14.

PMID:
27297970
26.

Erratum to: Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection.

Montassier E, Al-Ghalith GA, Ward T, Corvec S, Gastinne T, Potel G, Moreau P, De La Cochetiere MF, Batard E, Knights D.

Genome Med. 2016 May 26;8(1):61. No abstract available.

27.

Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection.

Montassier E, Al-Ghalith GA, Ward T, Corvec S, Gastinne T, Potel G, Moreau P, de la Cochetiere MF, Batard E, Knights D.

Genome Med. 2016 Apr 28;8(1):49. doi: 10.1186/s13073-016-0301-4. Erratum in: Genome Med. 2016;8(1):61.

28.

Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.

Tadec L, Talarmin JP, Gastinne T, Bretonnière C, Miegeville M, Le Pape P, Morio F.

Mycoses. 2016 May;59(5):296-303. doi: 10.1111/myc.12470. Epub 2016 Jan 25.

PMID:
26806101
29.

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Lazarovici J, Dartigues P, Brice P, Obéric L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, André M, Mounier N, Fermé C.

Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1.

30.

Chemotherapy-driven dysbiosis in the intestinal microbiome.

Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, Moreau P, Potel G, de La Cochetière MF, Batard E, Knights D.

Aliment Pharmacol Ther. 2015 Sep;42(5):515-28. doi: 10.1111/apt.13302. Epub 2015 Jul 6.

31.

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.

Brissot E, Clavert A, Blin N, Roland V, Guillaume T, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Gaugler B, Moreau P, Mohty M.

Leukemia. 2015 Oct;29(10):2098-100. doi: 10.1038/leu.2015.64. Epub 2015 Mar 9. No abstract available.

PMID:
25748683
32.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S.

Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.

PMID:
25392158
33.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.

34.

Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications.

Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, Le Vacon F, de La Cochetière MF.

Aliment Pharmacol Ther. 2014 Sep;40(5):409-21. doi: 10.1111/apt.12878. Epub 2014 Jul 11. Review.

35.

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT.

Tessoulin B, Delaunay J, Chevallier P, Loirat M, Ayari S, Peterlin P, Le Gouill S, Gastinne T, Moreau P, Mohty M, Guillaume T.

Bone Marrow Transplant. 2014 Apr;49(4):567-71. doi: 10.1038/bmt.2013.233. Epub 2014 Feb 3.

PMID:
24488048
36.

16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation.

Montassier E, Batard E, Massart S, Gastinne T, Carton T, Caillon J, Le Fresne S, Caroff N, Hardouin JB, Moreau P, Potel G, Le Vacon F, de La Cochetière MF.

Microb Ecol. 2014 Apr;67(3):690-9. doi: 10.1007/s00248-013-0355-4. Epub 2014 Jan 9.

PMID:
24402367
37.

Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant.

Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, Stamatoullas A, Fornecker L, Deau B, Gastinne T, Reman O, Gaillard I, Borel C, Brice P, Fermé C.

Haematologica. 2013 Aug;98(8):1185-95. doi: 10.3324/haematol.2012.072090. Review.

38.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

39.

Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.

Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF.

Eur J Clin Microbiol Infect Dis. 2013 Jul;32(7):841-50. doi: 10.1007/s10096-013-1819-7. Epub 2013 Jan 25. Review.

PMID:
23354675
40.

Staging and monitoring in the treatment of lymphomas.

Dupas B, Augeul-Meunier K, Frampas E, Bodet-Milin C, Gastinne T, Le Gouill S.

Diagn Interv Imaging. 2013 Feb;94(2):145-57. doi: 10.1016/j.diii.2012.12.009. Epub 2013 Jan 16.

41.

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).

Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, Clavert A, Tessoulin B, Dubruille V, Mahe B, Roland V, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Chevallier P.

Eur J Haematol. 2013 Mar;90(3):177-86. doi: 10.1111/ejh.12049. Epub 2013 Jan 27.

PMID:
23301689
42.

The role of FDG-PET scanning in assessing lymphoma in 2012.

Bodet-Milin C, Eugène T, Gastinne T, Bailly C, Le Gouill S, Dupas B, Kraeber-Bodéré F.

Diagn Interv Imaging. 2013 Feb;94(2):158-68. doi: 10.1016/j.diii.2012.12.005. Epub 2013 Jan 5.

43.

Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.

Lemieux E, Hulin C, Caillot D, Tardy S, Dorvaux V, Michel J, Gastinne T, Rossi C, Legouge C, Touzeau C, Planche L, Loirat M, Lafon I, Moreau P.

Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9. doi: 10.1016/j.bbmt.2012.11.013. Epub 2012 Nov 24.

44.

Safety and efficacy of rituximab in steroid-refractory chronic GVHD.

Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M.

Bone Marrow Transplant. 2013 May;48(5):734-6. doi: 10.1038/bmt.2012.203. Epub 2012 Oct 22. No abstract available.

PMID:
23085828
45.

FDG-PET in Follicular Lymphoma Management.

Bodet-Milin C, Eugène T, Gastinne T, Frampas E, Le Gouill S, Kraeber-Bodéré F.

J Oncol. 2012;2012:370272. doi: 10.1155/2012/370272. Epub 2012 Jul 30.

46.

Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

Peterlin P, Leux C, Gastinne T, Roland V, Mahé B, Dubruille V, Delaunay J, Chevallier P, Guillaume T, Blin N, Ayari S, Clavert A, Mohty M, Dousset C, Milpied N, Harousseau JL, Moreau P, Wuilleme S, Moreau A, Le Gouill S.

Transplantation. 2012 Aug 15;94(3):295-301.

PMID:
22797728
47.

Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.

Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM.

Leuk Lymphoma. 2013 Jan;54(1):76-82. doi: 10.3109/10428194.2012.701737. Epub 2012 Jul 9.

PMID:
22680774
48.

Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity.

Guillaume T, Gaugler B, Chevallier P, Delaunay J, Ayari S, Clavert A, Rialland F, Le Gouill S, Blin N, Gastinne T, Mahé B, Dubruille V, Moreau P, Mohty M.

Bone Marrow Transplant. 2012 Aug;47(8):1112-7. doi: 10.1038/bmt.2011.231. Epub 2011 Nov 28.

PMID:
22120986
49.

Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?

Le Gouill S, Mohty M, Guillaume T, Gastinne T, Moreau P.

Semin Hematol. 2011 Jul;48(3):227-39. doi: 10.1053/j.seminhematol.2011.03.009. Review.

PMID:
21782065
50.

Invasive Myceliophthora thermophila infection mimicking invasive aspergillosis in a neutropenic patient: a new cause of cross-reactivity with the Aspergillus galactomannan serum antigen assay.

Morio F, Fraissinet F, Gastinne T, Le Pape P, Delaunay J, Sigler L, Gibas CF, Miegeville M.

Med Mycol. 2011 Nov;49(8):883-6. doi: 10.3109/13693786.2011.584218. Epub 2011 May 30.

PMID:
21619496

Supplemental Content

Loading ...
Support Center